HG2 treatment at various doses, along with nintedanib treatment, showed superior anti-pulmonary fibrosis effects, and the 400 mg/kg HG2 group showed the best performance (Figures 8D, E). The gene discussed is PKD1P2; the disease is pulmonary fibrosis.